Effect of nintedanib thermo-sensitive hydrogel on neovascularization in alkali burn rat model.

alkali burn cornea neovascularization nintedanib rat

Journal

International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860

Informations de publication

Date de publication:
2020
Historique:
received: 14 01 2020
accepted: 13 04 2020
entrez: 23 6 2020
pubmed: 23 6 2020
medline: 23 6 2020
Statut: epublish

Résumé

To investigate the effects of nintedanib thermo-sensitive hydrogel (NTH) on neovascularization and related markers in corneal alkali burns of Wistar rats. NTH was prepared by grinding, and its phase-transition temperature was determined. Thirty specific-pathogen-free Wistar rats served as a model of corneal alkali burn in the right eye were randomly divided into 3 groups ( The phase-transition temperature of nintedanib obtained by grinding was 37°C after adding artificial tears. The results of the alkali burn model indicated that the growth rate of neovascularization in the NTH group was slower than that in the model group, and the neovascularization area was significantly smaller than that in the model group ( NTH becomes colloidal at body temperature, which is beneficial for releasing the drug slowly and can significantly inhibit the neovascularization of corneal induced by alkali burn in rats.

Identifiants

pubmed: 32566497
doi: 10.18240/ijo.2020.06.04
pii: ijo-13-06-879
pmc: PMC7270255
doi:

Types de publication

Journal Article

Langues

eng

Pagination

879-885

Informations de copyright

International Journal of Ophthalmology Press.

Références

Drug Des Devel Ther. 2015 Apr 22;9:2311-20
pubmed: 25960634
PLoS One. 2019 Aug 6;14(8):e0218632
pubmed: 31386668
FEBS Lett. 2001 Nov 16;508(2):187-90
pubmed: 11718713
Ophthalmology. 2015 Sep;122(9):1846-53.e5
pubmed: 26143666
Sci Pharm. 2011 Jun;79(2):351-8
pubmed: 21773071
Pharmaceutics. 2018 Sep 12;10(3):
pubmed: 30213143
Ophthalmology. 2014 Mar;121(3):656-66
pubmed: 24314839
Eye Vis (Lond). 2017 Dec 10;4:28
pubmed: 29234686
Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1784-93
pubmed: 2759793
Surv Ophthalmol. 2012 Sep;57(5):415-29
pubmed: 22898649
Drugs. 2015 Jul;75(10):1131-40
pubmed: 26063212
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
Saudi Pharm J. 2019 Nov;27(7):990-999
pubmed: 31997906
J Med Life. 2015 Oct-Dec;8(4):444-8
pubmed: 26664467
Iran J Pharm Res. 2015 Spring;14(2):347-58
pubmed: 25901142
Rom J Ophthalmol. 2019 Jan-Mar;63(1):15-22
pubmed: 31198893
Prog Retin Eye Res. 2010 Nov;29(6):500-19
pubmed: 20488255

Auteurs

Yan Gong (Y)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Guo-Hai Wu (GH)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Ling-Yi Zhang (LY)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Zhe Zhang (Z)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Yan-Hong Liao (YH)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Xiao-Tian Liu (XT)

Department of Ophthalmology, Ningbo Eye Hospital, Ningbo 315040, Zhejiang Province, China.

Classifications MeSH